Documenting work, sharing experiences, and open-sourcing! Speed up! Committed to ensuring that every step of our design is theoretically supported! Star and follow = progress together. Be sure to check the comments section, as some colleagues will discuss and supplement there, enriching this theoretical library together! Documentation is getting more concise! CPU is burning up … Read more
Recently, there has been a piece of news that is quite eye-catching.On November 19, 2025, the ADC biotechnology company Lifordi Immunotherapeutics announced the completion of a new round of strategic financing amounting to $42 million. The funds will primarily be used for ADCs beyond oncology—specifically, LFD-200, which targets VISTA, one of the most competitive emerging … Read more
🔬 Introduction From Paul Ehrlich’s concept of the “magic bullet” in the early 20th century to the approval of the first ADC drug Mylotarg in 2000, antibody-drug conjugates (ADCs) have undergone a century of evolution and have become a “star therapy” in the field of precision oncology. This “biological missile,” which combines the targeting ability … Read more
In the world of oncology, HER2 (human epidermal growth factor receptor 2) used to represent a simple boundary—positive meant eligibility for treatment; negative meant no access to targeted therapy.. However, with the advent of antibody-drug conjugates (ADCs), this boundary has begun to blur. This article published in Gynecologic Oncology illustrates that:HER2 is no longer a … Read more
ADC is known as precision therapy, which delivers drugs precisely to tumor cells through targeted antibodies, maximizing the destruction of tumors while minimizing damage to normal tissues. In the design of ADC, antibodies are responsible for “navigation,” while the payload (toxin) is the true “terminator.” This article will discuss the classification of mainstream ADC payloads, … Read more
Linear regression is the foundation of the classic least squares method, Kalman filter, and Wiener filter. It was the first algorithm I encountered during my graduate studies, and I first used it while working on a project for my advisor. After entering the workforce, I found that these algorithms are ubiquitous in engineering. Unfortunately, many … Read more
Recently, I studied the ABA problem in lock-free stacks, and I would like to share my insights.Lock-free data structures are data structures implemented using CAS (Compare and Swap). In contrast, traditional data structures use locks.On CPUs with multiple hardware threads, lock-free data structures improve performance as the number of threads increases; whereas, lock-based data structures … Read more
Good article to read: Abstract: In the past decade, antibody-drug conjugates (ADCs) have sparked a new wave of development in the biopharmaceutical market due to their high efficacy in cancer treatment. As of now, the U.S. Food and Drug Administration (FDA) has approved 13 types of ADCs for clinical treatment. The development of ADCs relies … Read more
ADC is known as precision therapy, which delivers drugs precisely to tumor cells through targeted antibodies, maximizing tumor destruction while minimizing damage to normal tissues. In the design of ADC, antibodies are responsible for “navigation,” while the payload (toxin) is the true “terminator.” This article will delve into the classification of mainstream ADC payloads, why … Read more
Introduction In recent years, two major breakthroughs in cancer treatment—Antibody-Drug Conjugates (ADC) and Bispecific Antibodies (referred to as “bispecifics”)—have demonstrated remarkable efficacy. So, if these two “star drugs” are used in combination, will they produce a stronger anti-cancer effect? Will the toxicity be compounded and difficult to control? A recent clinical study published in the … Read more